Version 1
: Received: 21 August 2024 / Approved: 21 August 2024 / Online: 22 August 2024 (12:20:12 CEST)
How to cite:
Giorgioni, L.; Ambrosone, A.; Cometa, M. F.; Salvati, A. L.; Nisticò, R.; Magrelli, A. Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility. Preprints2024, 2024081583. https://doi.org/10.20944/preprints202408.1583.v1
Giorgioni, L.; Ambrosone, A.; Cometa, M. F.; Salvati, A. L.; Nisticò, R.; Magrelli, A. Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility. Preprints 2024, 2024081583. https://doi.org/10.20944/preprints202408.1583.v1
Giorgioni, L.; Ambrosone, A.; Cometa, M. F.; Salvati, A. L.; Nisticò, R.; Magrelli, A. Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility. Preprints2024, 2024081583. https://doi.org/10.20944/preprints202408.1583.v1
APA Style
Giorgioni, L., Ambrosone, A., Cometa, M. F., Salvati, A. L., Nisticò, R., & Magrelli, A. (2024). Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility. Preprints. https://doi.org/10.20944/preprints202408.1583.v1
Chicago/Turabian Style
Giorgioni, L., Robert Nisticò and Armando Magrelli. 2024 "Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility" Preprints. https://doi.org/10.20944/preprints202408.1583.v1
Abstract
This manuscript explores significant advancements and emerging challenges in CAR T cell therapies, focusing on the production methodologies and regulatory complexities. The discussion highlights ongoing challenges like the lack of in vivo persistence, lengthy production times, and elevated costs associated with current CAR T cell therapies. It analyzes innovative solutions such as genetic engineering techniques aimed at enhancing cellular efficacy and endurance, alongside cutting-edge manufacturing processes, including closed systems and development of allogeneic products. These advancements hold promise for reducing costs and improving production efficiency, potentially increasing patient access to these transformative therapies globally. Furthermore, the manuscript underscores the necessity for expanding ongoing research and enhancing regulatory frameworks to fully realize and implement these innovations in CAR T cell manufacturing and bring these innovations to fruition.
Keywords
CAR T; manufacturing; hospital exemption
Subject
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
